had an improved overall survival with atezolizumab, bevacizumab, and chemotherapy combination, compared to bevacizumab and chemotherapy alone, with a median os of 13.3 and 9.4 months, respectively, hr 0.52. no improvement in overall survival was observed for patients with liver metastasis treated with chemotherapy and atezolizumab compared to patients treated with chemotherapy and bevacizumab. recent report about safety and patient-reported outcomes of atezolizumab plus chemotherapy and bevacizumab shows that this drug combination seems tolerable and with manageable toxicities. for patients with nsq nsclc with baseline liver metastases, the combination of chemotherapy, atezolizumab and bevacizumab could be an option to consider in the first line. society and culture drug cost controversy atezolizumab treatment costs on average us$13,200 per month in the united states, depending on the dosage schedule. despite updated data showing 30% more people with extensive stage small cell lung cancer have survived at 24 months, compared to those who received chemotherapy alone, canadian regulators had rejected funding for atezolizumab to treat extensive stage small-cell lung cancer "as too costly" followed by united kingdom also citing "drug's cost-effectiveness." however, u.k. reversed its previous decision and approved tecentriq for extensive stage small cell lung cancer after price reconsideration on 27 may 2020. research as of 2016, it is in clinical trials for colorectal cancer, melanoma, breast cancer, non-small-cell lung carcinoma, bladder cancer, renal cell carcinoma. promising results have been observed for melanoma and non-small-cell lung cancer, and bladder cancer. a phase i trial reported a 19% objective response rate in metastatic triple-negative breast cancer. as of 2019, atezolizumab is in trial for several types of cancer, such as pancreatic cancer, gastric cancer and ovarian cancer.